Abstract
Background
Irritable bowel syndrome (IBS) is a chronic disorder of gut–brain interaction characterized by abdominal pain associated with altered bowel habits. Conventional therapies often provide incomplete symptom relief, leading to increasing interest in next-generation approaches that target dietary triggers, central and enteric neuromodulation, psychological factors, and the intestinal microbiome.
Objective
This review evaluates the current evidence supporting low FODMAP diets, neuromodulators, digital cognitive behavioral therapy (CBT), and microbiome-directed therapies in IBS management, with emphasis on efficacy, mechanisms, safety, implementation, and long-term clinical applicability.
Methods
A narrative review of peer-reviewed literature was conducted using randomized controlled trials, systematic reviews, meta-analyses, and guideline-based evidence from databases including PubMed, the Cochrane Library, and major gastroenterology journals. Evidence was synthesized according to therapeutic category and clinical relevance.
Results
Low FODMAP dietary therapy demonstrates some of the strongest evidence among nonpharmacologic IBS interventions, with symptom response rates ranging from approximately 50% to 80% in appropriately selected patients. Neuromodulators, particularly tricyclic antidepressants, show measurable benefit for pain modulation and global symptom improvement through effects on the gut–brain axis. Digital CBT platforms provide symptom improvement comparable to conventional therapist-delivered CBT while improving treatment accessibility and scalability. Microbiome-based interventions, including probiotics, prebiotics, synbiotics, and fecal microbiota transplantation (FMT), remain promising but exhibit heterogeneity in efficacy and study quality.
Conclusion
Next-generation IBS therapies represent an important shift toward multidimensional and personalized care. Evidence supports the integration of dietary modification, neuromodulation, psychological therapy, and selected microbiome interventions into individualized treatment plans, although variability in treatment response and implementation challenges remain significant.
Keywords
Irritable bowel syndrome; disorders of gut–brain interaction; low FODMAP diet; neuromodulators; cognitive behavioral therapy; digital therapeutics; microbiome; probiotics; fecal microbiota transplantation
Introduction
Irritable bowel syndrome (IBS) is one of the most prevalent disorders of gut–brain interaction worldwide, affecting approximately 10–15% of the global population. The condition is characterized by recurrent abdominal pain associated with altered bowel habits in the absence of identifiable structural pathology. According to the Rome IV criteria, IBS is classified into constipation-predominant (IBS-C), diarrhea-predominant (IBS-D), mixed bowel habit (IBS-M), and unclassified subtypes.
IBS imposes a substantial clinical and socioeconomic burden. Patients frequently experience impaired quality of life, reduced work productivity, increased healthcare utilization, and significant psychological distress. Although IBS is not associated with increased mortality, symptom chronicity and unpredictability often contribute to long-term disability and emotional impairment.
The pathophysiology of IBS is multifactorial and incompletely understood. Current evidence implicates abnormalities in gut–brain signaling, visceral hypersensitivity, gastrointestinal dysmotility, altered intestinal permeability, immune activation, postinfectious changes, dysbiosis of the intestinal microbiome, and psychosocial stressors. These interacting mechanisms contribute to the heterogeneous clinical presentation observed across IBS populations.
Traditional IBS management historically focused on symptomatic treatment with antispasmodics, laxatives, antidiarrheal agents, and dietary advice. However, many patients continue to experience persistent symptoms despite standard therapies. This therapeutic gap has accelerated interest in more targeted and multidimensional interventions.
Recent advances in IBS management include structured dietary approaches such as the low fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP) diet; gut-directed neuromodulator therapy; digitally delivered cognitive behavioral therapy; and microbiome-based interventions. These approaches reflect a broader conceptual shift toward personalized and mechanism-based treatment.
This review examines the current evidence supporting these next-generation IBS therapies, including mechanisms of action, efficacy data, safety considerations, implementation barriers, and emerging future directions.
Low FODMAP Diet: Mechanisms, Evidence, and Clinical Application
Mechanistic Basis
The low FODMAP diet was developed to reduce the intake of short-chain carbohydrates that are poorly absorbed within the small intestine. These fermentable carbohydrates include fructans, galactooligosaccharides, lactose, excess fructose, and polyols such as sorbitol and mannitol.
Poor absorption of FODMAPs increases luminal osmotic activity and promotes rapid bacterial fermentation within the colon. These processes increase gas production and intraluminal water content, contributing to luminal distension, bloating, abdominal discomfort, and altered bowel habits. Patients with IBS demonstrate heightened visceral sensitivity, making them particularly susceptible to these effects.
The low FODMAP diet is generally implemented in three stages:
- Restriction phase: elimination of high-FODMAP foods for approximately 2–6 weeks.
- Reintroduction phase: systematic reintroduction of individual FODMAP groups to identify triggers.
- Personalization phase: development of a sustainable long-term dietary pattern based on individual tolerance.
The goal of therapy is not indefinite restriction but rather personalized symptom management while preserving nutritional adequacy and microbiome diversity.
Clinical Evidence
Multiple randomized controlled trials and meta-analyses support the efficacy of the low FODMAP diet in IBS.
Systematic reviews have demonstrated symptom improvement rates ranging from approximately 50% to 86%, particularly for abdominal pain, bloating, and global symptom burden. Meta-analytic evidence supports moderate improvements in overall IBS severity and quality of life compared with standard dietary advice.
Randomized controlled trials comparing low FODMAP diets with conventional dietary recommendations consistently demonstrate superior reductions in symptom severity scores and improved stool consistency. Benefits are often observed within several weeks of dietary initiation.
Several studies also demonstrate sustained symptom improvement following structured food reintroduction and dietary personalization. Long-term follow-up data suggest that many patients successfully transition from strict restriction to a liberalized individualized dietary pattern while maintaining symptom control.
Nutritional and Microbiome Considerations
Despite demonstrated efficacy, prolonged strict FODMAP restriction may reduce intake of fiber, prebiotic substrates, and selected micronutrients. Reduced abundance of beneficial bacterial species, particularly Bifidobacterium species, has been observed during strict restriction phases.
However, evidence suggests that microbiome alterations may partially reverse following systematic food reintroduction. Long-term nutritional deficiencies appear less common when dietary therapy is properly supervised.
Dietitian involvement substantially improves adherence, nutritional adequacy, and clinical outcomes. Specialized counseling helps patients avoid unnecessary dietary restriction and supports sustainable long-term implementation.
Practical Implementation Challenges
Implementation barriers include dietary complexity, limited access to trained gastrointestinal dietitians, social restrictions associated with eating outside the home, food affordability, and variability in patient adherence.
Digital tools, including smartphone applications and web-based food databases, have improved accessibility and patient education. These platforms assist with meal planning, food selection, and symptom tracking, facilitating adherence and individualized dietary modification.
Neuromodulators and the Gut–Brain Axis
Pathophysiologic Rationale
Neuromodulators are increasingly used in IBS because of their ability to influence gut–brain signaling, visceral hypersensitivity, gastrointestinal motility, and central pain processing.
The enteric nervous system and central nervous system communicate bidirectionally through neural, endocrine, and immune pathways. Dysregulation within this axis contributes to abnormal pain perception, stress-related symptom exacerbation, and altered bowel function.
Neuromodulators used in IBS include:
- Tricyclic antidepressants (TCAs)
- Selective serotonin reuptake inhibitors (SSRIs)
- Serotonin–norepinephrine reuptake inhibitors (SNRIs)
- Selected anticonvulsants and pain-modulating agents
These medications are often prescribed at lower doses than those used for psychiatric disorders.
Tricyclic Antidepressants
TCAs remain among the best-studied neuromodulators in IBS. Their therapeutic effects include modulation of visceral pain pathways, reduction of central pain amplification, anticholinergic slowing of intestinal transit, and improvement in sleep quality.
Clinical trials and meta-analyses demonstrate modest but clinically meaningful improvement in global IBS symptoms and abdominal pain with TCA therapy. Patients with IBS-D may derive particular benefit because of slowed intestinal transit associated with anticholinergic effects.
Typical IBS dosing strategies involve low nightly doses with gradual titration according to tolerability and symptom response.
Common adverse effects include:
- Dry mouth
- Constipation
- Sedation
- Dizziness
- Urinary retention
- Weight gain
Cardiac conduction abnormalities are uncommon at IBS doses but warrant caution in elderly individuals and patients with preexisting cardiovascular disease.
SSRIs and SNRIs
SSRIs and SNRIs primarily influence serotonergic signaling, which plays a major role in gastrointestinal motility and sensation. Approximately 90–95% of total body serotonin is located within the gastrointestinal tract.
Evidence supporting SSRIs in IBS is more variable than that for TCAs. Some studies suggest improvement in global well-being and psychological distress rather than direct gastrointestinal symptom reduction.
SSRIs may be more beneficial in IBS-C because of mild prokinetic effects. SNRIs such as duloxetine have shown potential benefit in pain-predominant IBS, although large-scale evidence remains limited.
Common adverse effects include:
- Nausea
- Insomnia
- Sexual dysfunction
- Headache
- Anxiety during initiation
Careful dose titration improves tolerability and reduces early treatment discontinuation.
Emerging Neuromodulatory Approaches
Additional agents under investigation include gabapentinoids such as pregabalin, which may reduce visceral hypersensitivity. Early studies demonstrate physiologic effects on rectal sensitivity, although clinical symptom improvements remain inconsistent.
Research into centrally acting therapies continues to evolve as understanding of gut–brain signaling mechanisms expands.
Digital Cognitive Behavioral Therapy in IBS
Psychological and Neurobiological Basis
Psychological stress is strongly associated with IBS symptom generation and exacerbation. Anxiety, depression, hypervigilance, catastrophic thinking, and maladaptive coping patterns are common among IBS populations.
Cognitive behavioral therapy aims to modify dysfunctional thought patterns and behaviors that perpetuate symptom amplification. Gut-directed CBT additionally incorporates education regarding gut–brain interactions, stress physiology, symptom reinterpretation, and behavioral coping strategies.
Digital CBT platforms deliver these interventions through internet-based or mobile applications, increasing scalability and accessibility.
Clinical Evidence
Multiple randomized controlled trials support the efficacy of digital CBT for IBS.
Digital interventions consistently demonstrate improvement in:
- Global IBS symptom severity
- Abdominal pain
- Anxiety and depression symptoms
- Quality of life
- Work and social functioning
Several studies report treatment outcomes comparable to traditional face-to-face CBT. Improvements frequently persist beyond completion of active therapy, suggesting durable acquisition of coping skills and behavioral modification.
Meta-analyses demonstrate moderate effect sizes for symptom improvement and quality-of-life enhancement across digital CBT programs.
Advantages of Digital Delivery
Digital CBT provides several practical advantages:
- Increased access for rural and underserved populations
- Reduced treatment costs
- Flexible scheduling and self-paced learning
- Reduced stigma associated with mental health treatment
- Scalability across healthcare systems
The expansion of telemedicine infrastructure has further accelerated adoption of digital psychological interventions.
Limitations and Adherence Challenges
Despite effectiveness, digital CBT programs face challenges related to patient engagement and retention. Dropout rates may be higher than in therapist-delivered interventions.
Adherence improves when programs incorporate:
- Interactive content
- Therapist guidance
- Automated reminders
- Symptom monitoring tools
- Peer or community support features
Digital literacy and technology access may also influence participation, particularly among older adults and socioeconomically disadvantaged populations.
Microbiome-Based Interventions
Gut Microbiome Alterations in IBS
The intestinal microbiome plays a central role in gastrointestinal homeostasis through effects on metabolism, immune regulation, barrier integrity, and gut–brain signaling.
Patients with IBS demonstrate alterations in microbial diversity and composition compared with healthy individuals. Reported findings include reduced abundance of beneficial taxa such as Bifidobacterium and Lactobacillus species and increased representation of potentially pathogenic organisms.
These alterations may contribute to:
- Visceral hypersensitivity
- Increased intestinal permeability
- Low-grade mucosal inflammation
- Abnormal bile acid metabolism
- Altered short-chain fatty acid production
Such observations provide the rationale for microbiome-targeted therapies.
Probiotics
Probiotics are among the most extensively studied microbiome interventions in IBS.
Meta-analyses generally support modest improvement in:
- Global IBS symptoms
- Abdominal pain
- Bloating
- Flatulence
However, results vary substantially because of heterogeneity in bacterial strains, dosing regimens, treatment duration, and study methodology.
Evidence suggests that multi-strain probiotic formulations may provide greater symptom improvement than single-strain preparations in some populations.
Bifidobacterium-containing preparations and selected Lactobacillus strains demonstrate some of the most consistent evidence for benefit.
Overall safety profiles are favorable in immunocompetent individuals.
Prebiotics and Synbiotics
Prebiotics selectively promote growth of beneficial intestinal bacteria through provision of fermentable substrates. Synbiotics combine probiotics with prebiotic compounds.
Studies suggest modest improvements in IBS symptoms with synbiotic interventions, although gastrointestinal side effects such as bloating and gas may occur during early treatment.
Clinical implementation remains challenging because several commonly used prebiotics are themselves high-FODMAP compounds and may exacerbate symptoms in sensitive patients.
Fecal Microbiota Transplantation
FMT involves transfer of processed stool from healthy donors into the gastrointestinal tract of recipients to modify microbiome composition.
Although early observational studies suggested potential benefit in IBS, larger randomized controlled trials have produced inconsistent and generally disappointing results.
Current evidence does not support routine use of FMT in IBS outside investigational settings.
Safety concerns include:
- Transmission of infectious organisms
- Multidrug-resistant bacterial infection
- Procedure-related complications
- Uncertain long-term microbiome effects
Consequently, FMT remains primarily reserved for recurrent Clostridioides difficile infection rather than standard IBS management.
Comparative Therapeutic Overview
| Treatment Modality | Approximate Response Rate | Key Advantages | Major Limitations |
| Low FODMAP diet | 50–80% | Strong evidence base; rapid symptom improvement | Complex implementation; dietary restriction burden |
| Tricyclic antidepressants | 55–70% | Effective for pain modulation; inexpensive | Anticholinergic adverse effects |
| SSRIs/SNRIs | 40–60% | Useful in patients with psychological comorbidity | Mixed efficacy data |
| Digital CBT | 45–65% | Accessible; durable behavioral benefits | Engagement and adherence challenges |
| Probiotics | 40–55% | Favorable safety profile | Strain-specific variability |
| FMT | 20–30% | Potential investigational role | Limited evidence and safety concerns |
Clinical Integration and Personalized Treatment
Patient Phenotyping
IBS is highly heterogeneous, making patient phenotyping critical for treatment selection.
Patients with strong food-related symptom patterns may respond particularly well to dietary interventions. Individuals with significant anxiety, hypervigilance, or maladaptive coping behaviors may derive greater benefit from CBT-based therapies.
Neuromodulator selection may be influenced by IBS subtype:
- TCAs are often favored in IBS-D because of transit-slowing effects.
- SSRIs may be more suitable in IBS-C because of prokinetic properties.
Microbiome-directed therapies currently lack validated predictive biomarkers, limiting precision-based selection.
Combination Therapy
Many patients benefit from multimodal treatment strategies targeting complementary pathophysiologic pathways.
Potentially synergistic combinations include:
- Low FODMAP diet plus probiotics
- Neuromodulators plus CBT
- Dietary therapy plus psychological intervention
Stepped-care approaches may optimize resource utilization and patient adherence while reducing unnecessary pharmacologic escalation.
Special Populations
Older Adults
Older patients may experience increased sensitivity to anticholinergic adverse effects from TCAs and may require lower starting doses.
Patients with Inflammatory Bowel Disease
Functional gastrointestinal symptoms commonly persist in patients with inflammatory bowel disease in remission. Careful nutritional assessment is important when implementing dietary restriction in this population.
Adolescents
Digital CBT platforms adapted for adolescents demonstrate promising engagement and efficacy, particularly when family support is incorporated.
Pregnancy
Dietary and behavioral interventions assume greater importance during pregnancy because of medication safety considerations.
Cost-Effectiveness and Healthcare System Considerations
IBS generates substantial direct and indirect healthcare costs through physician visits, diagnostic testing, medication use, absenteeism, and reduced productivity.
Digital CBT platforms demonstrate favorable cost-effectiveness because development costs are distributed across large user populations. Dietary interventions may incur significant upfront costs related to dietitian counseling but may reduce long-term healthcare utilization.
Generic neuromodulators remain relatively inexpensive, although monitoring and management of adverse effects contribute to overall treatment costs.
Healthcare system implementation remains limited by:
- Shortage of trained gastrointestinal dietitians
- Limited behavioral health access
- Fragmented multidisciplinary care
- Insufficient provider training in disorders of gut–brain interaction
Integrated multidisciplinary care models may improve outcomes and reduce healthcare inefficiencies.
Current Challenges and Research Limitations
Several limitations affect interpretation of the current evidence base.
Most IBS intervention trials involve relatively short follow-up durations, limiting assessment of long-term effectiveness and sustainability. Placebo response rates in IBS trials are consistently high and complicate evaluation of modest treatment effects.
Study heterogeneity also limits comparison across interventions because of:
- Variable symptom scales
- Different response definitions
- Diverse patient populations
- Inconsistent treatment protocols
Biomarker development remains an important unmet need. Reliable predictors of treatment response could substantially improve individualized therapy and reduce trial-and-error management.
Digital health regulation, probiotic quality control, and long-term microbiome safety monitoring also represent ongoing clinical and regulatory challenges.
Future Directions
Personalized Medicine
Future IBS management will likely increasingly incorporate precision medicine approaches.
Potential predictive tools under investigation include:
- Genetic polymorphisms affecting neurotransmitter signaling
- Microbiome profiling
- Metabolomic signatures
- Inflammatory biomarkers
- Psychological profiling instruments
Machine learning algorithms integrating clinical and biologic data may eventually facilitate individualized treatment selection.
Emerging Therapeutic Targets
Novel therapies under investigation include:
- Vagal nerve stimulation
- Cannabinoid receptor modulation
- Engineered microbiome therapeutics
- Targeted metabolite therapies
- Advanced gut-directed behavioral technologies
These approaches aim to address specific mechanistic pathways underlying IBS symptom generation.
Technological Integration
Artificial intelligence and wearable health technologies may further enhance IBS management through:
- Real-time symptom tracking
- Behavioral monitoring
- Personalized digital intervention delivery
- Predictive flare detection
- Remote outcome assessment
Virtual reality-assisted stress management and ecological momentary assessment platforms also represent evolving areas of interest.
Conclusion
Next-generation IBS therapies reflect a major transition from purely symptom-based treatment toward multidimensional and mechanism-oriented care. Low FODMAP dietary therapy currently possesses one of the strongest evidence bases among nonpharmacologic interventions, while neuromodulators provide clinically meaningful improvement through modulation of gut–brain signaling and visceral pain pathways.
Digital CBT has emerged as an effective and scalable therapeutic option capable of improving accessibility to evidence-based psychological care. Microbiome-based therapies remain promising, although variability in study quality, strain specificity, and long-term safety continue to limit broad clinical adoption.
No single intervention provides universal efficacy in IBS because of the condition’s marked heterogeneity. Individualized treatment selection, multidisciplinary care integration, and multimodal therapeutic strategies are increasingly recognized as central components of effective IBS management.
Future advances will likely depend on improved patient phenotyping, development of predictive biomarkers, expansion of digital health technologies, and continued exploration of the gut–brain–microbiome axis.
References
Almazar, A. E., Leo, M., Brenner, D. M., & Grover, M. (2018). Digital health applications in functional GI disorders: Current understanding and future directions. Digestive Diseases and Sciences, 63(11), 2969–2980.
Böhn, L., Störsrud, S., Liljebo, T., Collin, L., Lindfors, P., Törnblom, H., & Simrén, M. (2015). Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: A randomized controlled trial. Gastroenterology, 149(6), 1399–1407.
Bonnert, M., Olen, O., Lalouni, M., Hedman-Lagerlöf, E., Särnholm, J., Serlachius, E., & Ljótsson, B. (2019). Internet-delivered cognitive behavior therapy for adolescents with irritable bowel syndrome: A randomized controlled trial. American Journal of Gastroenterology, 114(9), 1436–1447.
Brennan, B. P., Fogarty, K. V., Roberts, J. L., Reynolds, K. A., Pope, H. G., & Hudson, J. I. (2009). Duloxetine in the treatment of irritable bowel syndrome: An open-label pilot study. Human Psychopharmacology, 24(8), 633–637.
Drossman, D. A., Tack, J., Ford, A. C., Szigethy, E., Törnblom, H., & Van Oudenhove, L. (2018). Neuromodulators for functional gastrointestinal disorders (disorders of gut-brain interaction): A Rome Foundation working team report. Gastroenterology, 154(4), 1140–1171.
Ducrotté, P., Sawant, P., & Jayanthi, V. (2012). Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome. World Journal of Gastroenterology, 18(30), 4012–4018.
El-Salhy, M., Hatlebakk, J. G., Gilja, O. H., Kristoffersen, A. B., & Hausken, T. (2020). Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study. Gut, 69(5), 859–867.
Everitt, H. A., Landau, S., O’Reilly, G., Sibelli, A., Hughes, S., Windgassen, S., et al. (2019). Assessing telephone-delivered cognitive-behavioural therapy and web-delivered CBT versus treatment as usual in irritable bowel syndrome (ACTIB): A multicentre randomised trial. Gut, 68(9), 1613–1623.
Ford, A. C., Harris, L. A., Lacy, B. E., Quigley, E. M., & Moayyedi, P. (2018). Systematic review with meta-analysis: The efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Alimentary Pharmacology & Therapeutics, 48(10), 1044–1060.
Ford, A. C., Lacy, B. E., Harris, L. A., Quigley, E. M., & Moayyedi, P. (2019). Effect of antidepressants and psychological therapies in irritable bowel syndrome: An updated systematic review and meta-analysis. American Journal of Gastroenterology, 114(1), 21–39.
Ford, A. C., Sperber, A. D., Corsetti, M., & Camilleri, M. (2020). Irritable bowel syndrome. Lancet, 396(10263), 1675–1688.
Gibson, P. R., & Shepherd, S. J. (2010). Evidence-based dietary management of functional gastrointestinal symptoms: The FODMAP approach. Journal of Gastroenterology and Hepatology, 25(2), 252–258.
Halkjær, S. I., Christensen, A. H., Lo, B. Z. S., Browne, P. D., Günther, S., Hansen, L. H., & Petersen, A. M. (2018). Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: Results from a randomised, double-blind placebo-controlled study. Gut, 67(12), 2107–2115.
Harvie, R. M., Chisholm, A. W., Bisanz, J. E., Burton, J. P., Herbison, P., Schultz, K., & Frampton, C. M. (2017). Long-term irritable bowel syndrome symptom control with reintroduction of selected FODMAPs. World Journal of Gastroenterology, 23(25), 4632–4643.
Houghton, L. A., Fell, C., Whorwell, P. J., Jones, I., Sudworth, D. P., & Dobson, J. E. (2007). Effect of pregabalin on visceral sensation in hypersensitive patients with irritable bowel syndrome. Gut, 56(9), 1218–1225.
Hunt, M. G., Moshier, S., & Milonova, M. (2009). Brief cognitive-behavioral internet therapy for irritable bowel syndrome. Behaviour Research and Therapy, 47(9), 797–802.
Ladabaum, U., Sharabidze, A., Levin, T. R., Zhao, W. K., Chung, E., Bacchetti, P., et al. (2010). Citalopram provides little or no benefit in nondepressed patients with irritable bowel syndrome. Clinical Gastroenterology and Hepatology, 8(1), 42–48.
Ljótsson, B., Falk, L., Vesterlund, A. W., Hedman, E., Lindfors, P., Rück, C., et al. (2010). Internet-delivered exposure and mindfulness-based therapy for irritable bowel syndrome: A randomized controlled trial. Behaviour Research and Therapy, 48(6), 531–539.
Marsh, A., Eslick, E. M., & Eslick, G. D. (2016). Does a diet low in FODMAPs reduce symptoms associated with functional gastrointestinal disorders? A systematic review and meta-analysis. European Journal of Nutrition, 55(3), 897–906.
O’Keeffe, M., Jansen, C., Martin, L., Williams, M., Seamark, L., Staudacher, H. M., et al. (2018). Long-term impact of the low-FODMAP diet on gastrointestinal symptoms, dietary intake, patient acceptability, and healthcare utilization in irritable bowel syndrome. Neurogastroenterology & Motility, 30(1), e13154.
Pittayanon, R., Lau, J. T., Yuan, Y., Leontiadis, G. I., Tse, F., Surette, M., & Moayyedi, P. (2019). Gut microbiota in patients with irritable bowel syndrome: A systematic review. Gastroenterology, 157(1), 97–108.
Qin, H. Y., Cheng, C. W., Tang, X. D., & Bian, Z. X. (2014). Impact of psychological stress on irritable bowel syndrome. World Journal of Gastroenterology, 20(39), 14126–14131.
Ruepert, L., Quartero, A. O., de Wit, N. J., van der Heijden, G. J., Rubin, G., & Muris, J. W. (2011). Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database of Systematic Reviews, 8, CD003460.
Staudacher, H. M., Irving, P. M., Lomer, M. C., & Whelan, K. (2014). Mechanisms and efficacy of dietary FODMAP restriction in IBS. Nature Reviews Gastroenterology & Hepatology, 11(4), 256–266.
Staudacher, H. M., Lomer, M. C., Anderson, J. L., Barrett, J. S., Muir, J. G., Irving, P. M., & Whelan, K. (2012). Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome. Journal of Nutrition, 142(8), 1510–1518.
Staudacher, H. M., Lomer, M. C., Farquharson, F. M., Louis, P., Fava, F., Franciosi, E., et al. (2017). A diet low in FODMAPs reduces symptoms in patients with irritable bowel syndrome and a probiotic restores Bifidobacterium species: A randomized controlled trial. Gastroenterology, 153(4), 936–947.
Wilson, B., Rossi, M., Dimidi, E., & Whelan, K. (2019). Prebiotics in irritable bowel syndrome and other functional bowel disorders in adults: A systematic review and meta-analysis of randomized controlled trials. American Journal of Clinical Nutrition, 109(4), 1098–1111.
Zhang, T., Zhang, C., Zhang, J., Sun, F., & Duan, L. (2020). Efficacy of probiotics for irritable bowel syndrome: A systematic review and network meta-analysis. Frontiers in Cellular and Infection Microbiology, 10, 200.
